SwanBio Therapeutics

SwanBio Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 13 subsidiaries including Achilles Therapeutics, Anaveon and Autolus Therapeutics.

They are in:

• Biotechnology86%
• Holding7%
• Other7%

Acquisition, funding and merger involving Syncona.

• Syncona has announced the acquisition of Beacon Therapeutics  (posted on October 28 2022).

View the org chart displaying its 6 main executives

Most searched biographies at SwanBio Therapeutics

• David Weiner, Chief Medical Officer
• Janet Ogden, Head of Portfolio Development
• Karen Kozarsky, Chief Scientific Officer

Popular executive movements at SwanBio Therapeutics

• Topher Brooke has joined the company as Chief Operating Officer  (posted on October 16 2023).

Create your alert
to follow the executive moves at SwanBio Therapeutics.

Syncona has 2,288 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).
• Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by SwanBio Therapeutics

Social media about SwanBio Therapeutics

• SwanBio Therapeutics on Wikipedia, Google News & Yahoo Finance
• SwanBio Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Topher Brooke

Call SwanBio Therapeutics at +1 703...

View the org chart

Register to receive your alert

Report an error